Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology—update 2014
-
- John E. Morley
- Divisions of Geriatric Medicine and Endocrinology St. Louis University School of Medicine 1402 S. Grand Blvd., M238 63104 St. Louis MO
-
- Stefan D. Anker
- Department of Innovative Clinical Trials University Medical Centre Göttingen Göttingen
-
- Stephan von Haehling
- Department of Innovative Clinical Trials University Medical Centre Göttingen Göttingen
説明
<jats:sec><jats:label /><jats:p>Sarcopenia is now defined as a decline in walking speed or grip strength associated with low muscle mass. Sarcopenia leads to loss of mobility and function, falls, and mortality. Sarcopenia is a major cause of frailty, but either condition can occur without the other being present. Sarcopenia is present in about 5 to 10 % of persons over 65 years of age. It has multiple causes including disease, decreased caloric intake, poor blood flow to muscle, mitochondrial dysfunction, a decline in anabolic hormones, and an increase in proinflammatory cytokines. Basic therapy includes resistance exercise and protein and vitamin D supplementation. There is now a simple screening test available for sarcopenia—SARC‐F. All persons 60 years and older should be screened for sarcopenia and treated when appropriate.</jats:p></jats:sec>
収録刊行物
-
- Journal of Cachexia, Sarcopenia and Muscle
-
Journal of Cachexia, Sarcopenia and Muscle 5 (4), 253-259, 2014-10-22
Wiley
